Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
Mation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10541657		
	Filing Date		2006-03-03		
	First Named Inventor	Robei	rt M. Jones		
	Art Unit		1624		
	Examiner Name	Noble	E. Jarrell		
	Attorney Docket Number	er	20750-0007US1/034.US5.PCT		

U.S.PATENTS								Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	of cited Document			es,Columns,Lines where vant Passages or Relevant res Appear		
	1										
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite N	Publication Number				cited Document		es,Columns,Lines where vant Passages or Relevant es Appear			
	1										
If you wis	h to add	additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	button	Add		
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	I I	Foreign Document Country Kind Code <sup>2</sup> i Code <sup>4</sup>		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		T5		
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials*  Cite No  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10541657		
Filing Date		2006-03-03		
First Named Inventor	Robe	Robert M. Jones		
Art Unit		1624		
Examiner Name	Noble E. Jarrell			
Attorney Docket Number		20750-0007US1/034.US5.PCT		

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Examiner Signature /Noble Jarrell/		Date Considered	01/11/2011				
EXAMINER SIGNATURE							
If you wish to a	add add	ditional non-patent literature document citation information pl	lease click the Add b	outton Add			
8	SIGMA-ALDRICH, catalog entry for 4,5-diamino-6-hydroxy-2-mercaptopyrimidine hemisulfate salt hydrate (392464); 1 page; retrieval date March 16, 2010						
7	SIGMA-ALDRICH, catalog entry for 2-amino-6-hydroxy-2-mercaptopyrimidine monohydrate (catalog no. A57406); 1 page; retrieval date March 16, 2010						
6		SIGMA-ALDRICH, catalog entry for 2-amino-6-chloro-4-pyrimidinol hydrate (catalog no. 07460); 1 page; retrieval date March 16, 2010					
5		SIGMA-ALDRICH, catalog entry for 4,6-diamino-2-mercaptopyrimidine hydrate (catalog no. 125830); 1 page; retrieval date March 16, 2010					
4		QUESADA et al, 2-Amino-5-nitro-4,6-dipiperidionpyrimidinium hydrogensulfate monohydrate, Acta Cryst, 2003, C59, 102-104 (Abstract; 1 page)					
3		MORISSETTE et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, Adv. Drug Delivery Reviews, 2004, 56, 275-300.					
2		GUILLORY, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," in: Polymorphism in Pharmaceutical Solids, ed. Harry G. Brittan, Vol. 95, Marcel Dekker, Inc., New York, 1999, pp. 202-209.					
1	GOTTLIEB, et al., "NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities" J. Org. Chem., 1997, 62, 7512-7515.						